NCT03785223已完成4 期
A 14 Week, Randomized, Placebo-Controlled Cross-Over Study of Methylphenidate Hydrochloride Controlled Release Capsules in Adult ADHD With and Without Anxiety Disorder Comorbidity
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Attention Deficit and Hyperactivity Rating Scale - 5
研究概览
简要总结
Other psychiatric disorders, including anxiety, often co-occur with adult ADHD; with 85% of ADHD patients having at least one other psychiatric condition. The presence of a co-occurring anxiety disorder has been associated with additive clinical effects, leading to more global impairment, poorer outcome, greater resistance to treatment and increased costs of illness. Stimulants are effective first-line treatments for adult ADHD patients, however the literature has mostly examined these treatments in pure ADHD populations (i.e. without other psychiatric disorders). Thus, there is little information to guide physicians in making treatment decisions for patients with ADHD and a co-occurring condition.
This trial aims to evaluate the efficacy and safety of methylphenidate hydrochloride controlled release capsules (Foquest) in treating adults aged 18-65 years with DSM-5 ADHD with and without a co-occurring anxiety disorder.The study uses a 14-week, randomized, placebo-controlled, cross-over design.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Outpatient men and women between 18 and 65 years who meet criteria for Current DSM-5 ADHDalone or with one of the following DSM-5 diagnoses: GAD, SAD,PD or Agoraphobia. Major Depressive Disorder or Persistent Depressive Disorder will be allowed, providing the severity is considered moderate or less, as defined by a score on the Montgomery Depressive Rating Scale-MADRS score of ≤
- •ADHD rating scale for DSM-5 (ADHD-5-RS) score ≥
- •Concomitant treatment with selective serotonin reuptake inhibitors (SSRI's), serotonin noradrenaline reuptake inhibitors (SNRI's), benzodiazepines, beta-blockers, atypical anti-psychotics, anti-epileptics is allowed, provided the dose has been stable for 8 weeks prior to study entry. Dose changes of allowed concomitant medication should be avoided during the treatment phases of the study.
- •The ability to comprehend and satisfactorily comply with protocol requirements.
- •Written informed consent given prior to entering the baseline period of the study.
- •All women of child bearing potential must have a negative screening visit serum or urine pregnancy test and be using adequate contraception for the duration of the study. Medically acceptable forms of contraception include oral contraceptives, injectable or implantable methods, intrauterine devices or properly used barrier contraception. Additionally, the use of condoms is suggested as an adjunct to the methods previously addressed to provide additional protection against accidental pregnancy.
排除标准
- •Participants who currently fulfill criteria for a lifetime history of bipolar disorder, schizophrenia or other psychotic disorders, delirium, dementia and amnesic and other cognitive disorders, severe head injury, autism spectrum disorders, or are in a current agitated state.
- •Participants with a history of seizure disorders, or an unstable medical condition will also be excluded.
- •Participants with significant suicidal ideation (MADRS item 10 score > 3) or who have enacted suicidal behaviours within 6 months prior to intake will be excluded from study participation and referred for appropriate clinical intervention.
- •Current treatment with a stimulant.
- •A history of > 2 failed trials of adequately dosed psychostimulants for Adult ADHD.
- •Patients receiving current psychotherapy, including cognitive behavioural therapy for either ADHD or an anxiety disorder, within 4 weeks prior to the baseline period.
- •Patients who are known to be allergic to methylphenidate or components of methylphenidate hydrochloride, have known hypersensitivity or idiosyncrasy to methylphenidate hydrochloride.
- •Patients who have thyroid pathology, treatment of which has not been stabilized for at least 3 months.
- •MAO inhibitors within 3 weeks of the start of the baseline.
- •Individuals meeting criteria for current cannabis use disorder or substance use disorder will be excluded.
- •Current use of bupropion or tri-cyclic antidepressants, with the exception of clomipramine.
- •Current use of clonidine, modafinil or atomoxetine.
- •Previous intolerance or failure to respond to an adequate trial of methylphenidate hydrochloride controlled release capsules (defined as a minimum of 55mg per day for at least 4 weeks).
- •Patients who have a history or evidence of a medical condition that would expose them to an increase or significant adverse event or interfere with assessments of safety and efficacy during the course of the trial including: advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, or other pre-existing cardiac abnormalities or other serious cardiac problems.
- •Patients with a history of Glaucoma.
- •Sleep medications during the study period are excluded with the exception of zopiclone and zolpidem and melatonin.
- •Patients using any herbal psychoactive treatments, eg; St.John's Wort, Valerian, Kava Kava, or Chamomile Extract within 14 days prior to randomization.
- •Patients who have received electroconvulsive therapy within the previous 6 months.
- •Patients with any condition or on any therapy that in the investigator's opinion or as indicated in the methylphenidate hydrochlorideproduct label, that may pose a risk to the subject or interfere with the study objective.
- •Patients having clinically significant abnormal laboratory or ECG findings not resolved by the baseline examination.
- •Patients with a proximal family history of sudden, unexplained cardiac death.
研究组 & 干预措施
Methylphenidate Hydrochloride Controlled-Release Capsules
Experimental
Flexibly dosed at 25-100 mg per day
干预措施: Methylphenidate Hydrochloride Controlled-Release Capsules (Drug)
Placebo Capsules
Placebo Comparator
1-4 capsules daily
干预措施: Placebo Capsule (Drug)
结局指标
主要结局
Attention Deficit and Hyperactivity Rating Scale - 5
时间窗: Change from baseline to Week 12
The ADHD-RS-5 is a scale for children and adolescents that assesses the frequency and severity of ADHD symptoms and impairments based on criteria from the Diagnostic Statistics Manual 5. The measure will be adapted for use with adults as a clinician rated scale in this study. It consists of 18 items, rated on a 4-point scale from 0 (never or rarely) to 3 (very often). The items can be summed to obtain a total score (range: 0-54), an Inattention subscore (range:0-27), and a Hyperactivity-Impulsivity subscore (range: 0-27), with higher scores indicating greater frequency and severity of symptoms.
次要结局
- Quick Inventory of Depressive Symptoms (QID-SR-16)(Change from baseline to Week 12)
- Generalized Anxiety Disorder-7(Change from baseline to Week 12)
- Montgomery-Åsberg Depression Rating Scale (MADRS)(Change from baseline to Week 12)
- PTSD Checklist for DSM-5 (PCL-5)(Change from baseline to Week 12)
- Hamilton Anxiety Rating Scale (HAM-A)(Change from baseline to Week 12)
- Clinical Global Impression - Severity (CGI-S)(Change from baseline to Week 12)
- Clinical Global Impression - Improvement (CGI-I)(Change from baseline to Week 12)
- Cannabis Use Disorder Identification Test-Revised (CUDIT-R)(Change from baseline to Week 12)
- Barkley Adult ADHD Rating Scale (BAARS-IV)(Change from baseline to Week 12)
- Barkley Deficits in Executive Functioning Scale (BDEFS)(Change from baseline to Week 12)
- Overall Anxiety Severity and Impairment Scale (OASIS)(Change from baseline to Week 12)
- Obsessive Compulsive Inventory - Revised (OCI-R)(Change from baseline to Week 12)
- Panic and Agoraphobia Scale (PAS)(Change from baseline to Week 12)
- Pittsburgh Sleep Quality Index (PSQI)(Change from baseline to Week 12)
- Sheehan Disability Scale (SDS)(Change from baseline to Week 12)
- Social Phobia Inventory (SPIN)(Change from baseline to Week 12)
- Alcohol Use Disorders Identification Test (AUDIT)(Change from baseline to Week 12)
- Binge Eating Scale (BES)(Change from baseline to Week 12)
- Drug Abuse Screening Test (DAST)(Change from baseline to Week 12)
- Hoarding Rating Scale (HRS)(Change from baseline to Week 12)
- Weiss Functional Impairment Rating Scale-Self Report (WFIRS-S)(Change from baseline to Week 12)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
A Study to Learn About the Occurrence of ADHD in Adults With Mental Conditions and Their Quality of LifeAttention Deficit Hyperactivity Disorder (ADHD)NCT04943796Takeda224
已完成
不适用
Assessing QbTest Utility in ADHD: A Randomised Controlled TrialAttention Deficit Hyperactivity Disorder (ADHD)NCT02209116University of Nottingham267
尚未招募
不适用
Prevalence of Attention Deficit Hyperactivity Disorder and Its ComorbiditiesADHDNCT06146595Assiut University200
已完成
不适用
Group Dialectical Behavior Therapy as add-on Treatment for Adults With Attention Deficit/Hyperactive DisorderAttention Deficit Hyperactivity DisorderNCT03326427Hospital de Clinicas de Porto Alegre31
已完成
不适用
A Systematic Study of Assessment of Attention-Deficit/Hyperactivity Disorder (ADHD)Attention Deficit Hyperactivity DisorderNCT05588713Uppsala University142